Pedimacs第二年度报告:儿科机械循环支持注册研究——植入前特征与结局
Pedimacs数据库纳入2012年9月至2016年9月北美42家医院364例<19岁VAD植入患者,共432个装置。主要诊断为心肌病(61%)、先天性心脏病(21%)和心肌炎(11%);87%植入时为Intermacs 1或2级。近50%患者6个月内移植,总体死亡率19%,不良事件负担仍高。
要点
- Pedimacs为最大儿科VAD纵向注册,4年纳入364例<19岁患者。
- 植入时87%为Intermacs 1或2级,近50%在6个月内接受移植。
- 总体死亡率19%,不良事件仍是主要挑战,尤其复杂先心幼儿。
核心结论
- Pedimacs构成最大的儿科VAD纵向注册,植入前数据有助于建立共享方案以改善结局。
- 不良事件仍是主要挑战,尤其是在年幼危重且合并复杂先天性心脏病的儿童中。
研究设计与样本
- Pedimacs为美国国家心肺血液研究所资助的北美数据库,2012年9月至2016年9月纳入<19岁VAD植入患者。
- 共42家医院为364例患者植入432个装置,纳入FDA批准的耐用装置及临时支持装置。
- 中位随访2.2个月(范围1天至41.5个月)。
主要发现
- 诊断包括心肌病223例(61%)、心肌炎41例(11%)、先天性心脏病77例(21%),其中48例为单心室生理。
- 植入时87%为Intermacs患者概况1或2级;年龄分布:<1岁69例(19%)、1-6岁66例(18%)、6-10岁56例(15%)、11-19岁173例(48%)。
- 支持策略:左心室辅助装置293例(80%)、双心室装置55例(15%)、全人工心脏8例(2%)。
- 近50%患者在6个月内接受移植,总体死亡率为19%。
关键数值与推荐
- 体外连续流泵(n=60)植入中位年龄1.7(0.3-10.0)岁。
- 体外搏动泵(n=105)植入中位年龄1.7(0.4-5.3)岁。
- 植入式连续流泵(n=174)植入中位年龄15.0(11.3-16.9)岁。
临床怎么用
- 跨中心植入前数据可用于制定共享协议以改善儿科VAD结局。
- 需重点关注年幼危重及复杂先天性心脏病患者的不良事件管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Expanded use of pediatric ventricular assist devices (VADs) has decreased mortality in children awaiting heart transplantation. Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs), a National Heart, Lung, and Blood Institute-sponsored North American database, provides a platform to understand this emerging population. METHODS: Between September 2012 and September 2016, patients aged younger than 19 years who underwent VAD implantation were enrolled in Pedimacs. FDA approved durable devices as well as temporary support devices were included. The second annual report updates the current Pedimacs data. Patients implanted with temporary devices are included in Pedimacs and this analysis includes this group of paracorporeal continuous flow VADs. RESULTS: Over the 4 years, 42 hospitals implanted 432 devices in 364 patients less than 19 yrs of age. Diagnoses included cardiomyopathy in 223 (61%), myocarditis in 41 (11%), and congenital heart disease in 77 (21%), of which 48 had single-ventricle physiology. At implant, 87% were at Intermacs patient profile 1 or 2. The age distribution of children (59% male) supported on VAD included 69 (19%) aged younger than 1 year, 66 (18%) aged 1 to 6 years, 56 (15%) aged 6 to 10 years, and 173 (48%) aged 11 to 19 years. Median follow-up was 2.2 months (range, 1 day to 41.5 months). Median (interquartile) age at implant was 1.7 (0.3-10.0) years for paracorporeal continuous-flow pumps (n = 60), 1.7 (0.4-5.3) years for paracorporeal pulsatile pumps (n = 105), and 15.0 (11.3-16.9) years for implantable continuous-flow pumps (n = 174). Support strategies included LVAD in 293 (80%), biventricular device in 55 (15%), and total artificial heart in 8 (2%). Nearly 50% of patients underwent transplantation within 6 months, with overall mortality of 19%. Adverse event burden continues to be high. CONCLUSIONS: Pedimacs constitutes the largest longitudinal pediatric VAD registry. Preimplant data across centers will be helpful at creating shared protocols with which to improve outcomes. Adverse events continue to be the major challenge, especially among the young critically ill children with complex congenital disease.
引用
- Blume ED, VanderPluym C, Lorts A, et al. Second annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) report: Pre-implant characteristics and outcomes. J Heart Lung Transplant. 2017. PMID: 28965736. doi:10.1016/j.healun.2017.06.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。